Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 56
Healthy volunteers: yes

Brief summary:
The purpose of this study was to determine how two doses of lasmiditan affected the heart in healthy participants. The study also evaluated how much lasmiditan got into the blood stream and how long it took the body to get rid of it. Information about side effects was collected. The study lasted a maximum of 46 days for each participant, not including screening.

Detailed description:

Arms:
arm 1: A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods. arm 2: A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods. arm 3: Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods. arm 4: A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.

Interventions: intervention 1: Lasmiditan intervention 2: Lasmiditan intervention 3: Placebo intervention 4: Moxifloxacin
Intervention descriptions: intervention 1: 100 mg administered orally (PO) intervention 2: 400 mg administered PO intervention 3: Placebo administered for lasmiditan or moxifloxacin intervention 4: 400 mg moxifloxacin administered PO

Protocol document: